Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents
Christopher J Gill, Roger Baxter, Alessandra Anemona, Giuseppe Ciavarro, Peter Dull, Christopher J Gill, Roger Baxter, Alessandra Anemona, Giuseppe Ciavarro, Peter Dull
Abstract
The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or Menactra® (MCV4) (sanofi pasteur). The proportion of subjects with hSBA titers ≥8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.
Trial registration: ClinicalTrials.gov NCT00856297.
Figures
Study population flow diagram.
Immune responses to MenACWY-CRM or MCV4 at 1 and 22 months post vaccination. *MenACWY-CRM noninferior to MCV4. **MenACWY-CRM statistically higher than MCV4. Percentage of participants with human SBA titers ≥8 at 1 month post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccinees, contrasted with immune status of age-matched unvaccinated controls. Human SBA Geometric Mean Titers at 1 month and 22 months post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccines, contrast with immune stats of age-matched unvaccinated controls. Rabbit SBA Geometric Mean Titers at 1 month and 22 months post vaccination with MenACWY-CRM or MCV4, contrasted with immune status of age-matched unvaccinated controls.
Immune responses to MenACWY-CRM or MCV4 at 1 and 22 months post vaccination. *MenACWY-CRM noninferior to MCV4. **MenACWY-CRM statistically higher than MCV4. Percentage of participants with human SBA titers ≥8 at 1 month post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccinees, contrasted with immune status of age-matched unvaccinated controls. Human SBA Geometric Mean Titers at 1 month and 22 months post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccines, contrast with immune stats of age-matched unvaccinated controls. Rabbit SBA Geometric Mean Titers at 1 month and 22 months post vaccination with MenACWY-CRM or MCV4, contrasted with immune status of age-matched unvaccinated controls.
Immune responses to MenACWY-CRM or MCV4 at 1 and 22 months post vaccination. *MenACWY-CRM noninferior to MCV4. **MenACWY-CRM statistically higher than MCV4. Percentage of participants with human SBA titers ≥8 at 1 month post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccinees, contrasted with immune status of age-matched unvaccinated controls. Human SBA Geometric Mean Titers at 1 month and 22 months post vaccination in the full initial study population and 22 months post vaccination in a subset of vaccines, contrast with immune stats of age-matched unvaccinated controls. Rabbit SBA Geometric Mean Titers at 1 month and 22 months post vaccination with MenACWY-CRM or MCV4, contrasted with immune status of age-matched unvaccinated controls.
Source: PubMed